<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:47:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8163522" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8163522</identifier>
        <datestamp>2022-02-01</datestamp>
        <setSpec>jdr</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Dent Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Dent Res</journal-id>
              <journal-id journal-id-type="publisher-id">JDR</journal-id>
              <journal-id journal-id-type="hwp">spjdr</journal-id>
              <journal-title-group>
                <journal-title>Journal of Dental Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0022-0345</issn>
              <issn pub-type="epub">1544-0591</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8163522</article-id>
              <article-id pub-id-type="pmcid">PMC8163522</article-id>
              <article-id pub-id-type="pmc-uid">8163522</article-id>
              <article-id pub-id-type="pmid">33030089</article-id>
              <article-id pub-id-type="pmid">33030089</article-id>
              <article-id pub-id-type="doi">10.1177/0022034520962733</article-id>
              <article-id pub-id-type="publisher-id">10.1177_0022034520962733</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Reports</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Clinical</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title><italic>COMT</italic> Genotype and Efficacy of Propranolol for TMD
Pain: A Randomized Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Slade</surname>
                    <given-names>G.D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1-0022034520962733">1</xref>
                  <xref ref-type="aff" rid="aff2-0022034520962733">2</xref>
                  <xref ref-type="corresp" rid="corresp1-0022034520962733"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fillingim</surname>
                    <given-names>R.B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3-0022034520962733">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ohrbach</surname>
                    <given-names>R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4-0022034520962733">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hadgraft</surname>
                    <given-names>H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5-0022034520962733">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Willis</surname>
                    <given-names>J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5-0022034520962733">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7767-0959</contrib-id>
                  <name>
                    <surname>Arbes</surname>
                    <given-names>S.J.</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <xref ref-type="aff" rid="aff5-0022034520962733">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0968-0594</contrib-id>
                  <name>
                    <surname>Tchivileva</surname>
                    <given-names>I.E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1-0022034520962733">1</xref>
                  <xref ref-type="aff" rid="aff6-0022034520962733">6</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1-0022034520962733"><label>1</label>Center for Pain Research and Innovation,
Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA</aff>
              <aff id="aff2-0022034520962733"><label>2</label>Division of Pediatric and Public Health,
Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA</aff>
              <aff id="aff3-0022034520962733"><label>3</label>Department of Community Dentistry and
Behavioral Science, University of Florida, Gainesville, FL, USA</aff>
              <aff id="aff4-0022034520962733"><label>4</label>Department of Oral and Maxillofacial
Surgery, University at Buffalo, State University of New York, Buffalo, NY, USA</aff>
              <aff id="aff5-0022034520962733"><label>5</label>Rho Inc., Durham, NC, USA</aff>
              <aff id="aff6-0022034520962733"><label>6</label>Division of Oral and Craniofacial Health
Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill,
Chapel Hill, NC, USA</aff>
              <author-notes>
                <corresp id="corresp1-0022034520962733">G.D. Slade, UNC Adams School of Dentistry,
CB #7455, Chapel Hill, NC 27599, USA. Email:
<email>gary_slade@unc.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>8</day>
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>2</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>1</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
              <volume>100</volume>
              <issue>2</issue>
              <fpage>163</fpage>
              <lpage>170</lpage>
              <permissions>
                <copyright-statement>© International &amp; American Associations for Dental Research
2020</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder content-type="society">International &amp; American Associations
for Dental Research</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Propranolol is a nonselective β-adrenergic receptor antagonist that is
efficacious in reducing facial pain. There is evidence that its analgesic
efficacy might be modified by variants of the catechol-O-methyltransferase
(<italic>COMT</italic>) gene. We tested the hypothesis in a subset of 143
non-Hispanic Whites from a randomized controlled trial of patients with painful
temporomandibular disorder (TMD). Patients were genotyped for rs4680, a single
nucleotide polymorphism of <italic>COMT</italic>, and randomly allocated to
either propranolol 60 mg twice daily or placebo. During the 9-wk follow-up
period, patients recorded daily ratings of facial pain intensity and duration;
the product was computed as an index of facial pain. Postbaseline change in the
index at week 9 (the primary endpoint) was analyzed as a continuous variable and
dichotomized at thresholds of ≥30% and ≥50% reduction. Mixed models for repeated
measures tested for the genotype × treatment group interaction and estimated
means, odds ratios (ORs), and 95% confidence limits (95% CLs) of efficacy within
<italic>COMT</italic> genotypes assuming an additive genetic model. In
secondary analysis, the cumulative response curves were plotted for dichotomized
reductions ranging from ≥20% to ≥70%, and genotype differences in area under the
curve percentages (%AUC) were calculated to signify efficacy. Mean index
reduction did not differ significantly (<italic>P</italic> = 0.277) according to
genotype, whereas the dichotomized ≥30% reduction revealed greater efficacy
among G:G homozygotes (OR = 10.9, 95%CL = 2.4, 50.7) than among A:A homozygotes
(OR = 0.8, 95%CL = 0.2, 3.2) with statistically significant interaction
(<italic>P</italic> = 0.035). Cumulative response curves confirmed greater
(<italic>P</italic> = 0.003) efficacy for G:G homozygotes (%AUC difference =
43.7, 95%CL = 15.4, 72.1) than for A:A homozygotes (%AUC difference = 6.5, 95%CL
= -30.2, 43.2). The observed antagonistic effect of the A allele on
propranolol’s efficacy was opposite the synergistic effect hypothesized a
priori. This unexpected result highlights the need for better knowledge of
<italic>COMT’s</italic> role in pain pathogenesis if the gene is to be used
for precision-medicine treatment of TMD (ClinicalTrials.gov NCT02437383).</p>
              </abstract>
              <kwd-group>
                <kwd>facial pain</kwd>
                <kwd>chronic pain</kwd>
                <kwd>placebos</kwd>
                <kwd>adrenergic beta-antagonists</kwd>
                <kwd>pharmacogenetics</kwd>
                <kwd>genetic polymorphism</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="award1-0022034520962733">
                  <funding-source id="funding1-0022034520962733">
                    <institution-wrap>
                      <institution>National Institute of Dental and Craniofacial
Research</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000072</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding1-0022034520962733">U01-DE024169</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-0022034520962733">
              <title>Introduction</title>
              <p>Symptoms of painful temporomandibular disorder (TMD) are reported by 5% of U.S.
adults, one-fifth of whom use prescription medication to manage the pain (<xref rid="bibr30-0022034520962733" ref-type="bibr">Slade and Durham 2020</xref>).
However, analgesics for TMD lack efficacy (<xref rid="bibr24-0022034520962733" ref-type="bibr">Mujakperuo et al. 2010</xref>), and “action is
urgently needed to improve care for individuals with a TMD” (<xref rid="bibr25-0022034520962733" ref-type="bibr">National Academies of Sciences 2020</xref>). Yet,
formidable barriers restrict the development of new analgesics, including the many
years required to discover new analgesics and the high probability that they fail to
show efficacy in phase III trials (<xref rid="bibr3-0022034520962733" ref-type="bibr">Chaplan et al. 2010</xref>).</p>
              <p>Effective analgesics might instead be identified using strategies from precision
medicine (<xref rid="bibr26-0022034520962733" ref-type="bibr">Niculescu et al.
2019</xref>). One strategy is to repurpose drugs developed for other conditions,
using them to target biological pathways that modulate pain. Another strategy is to
tailor drug therapy based on patients’ genotypes (<xref rid="bibr38-0022034520962733" ref-type="bibr">Wilentz and Cowley 2017</xref>). Both strategies
are applicable to propranolol, a nonselective β-adrenergic receptor antagonist,
which was developed in the 1960s and is effective for migraine prevention (<xref rid="bibr16-0022034520962733" ref-type="bibr">He et al. 2017</xref>). Recent
findings from preclinical studies have shown that propranolol inhibits pain
processes that amplify trigeminal nociception (<xref rid="bibr18-0022034520962733" ref-type="bibr">Khasar et al. 1999</xref>; <xref rid="bibr29-0022034520962733" ref-type="bibr">Shields and Goadsby 2005</xref>; <xref rid="bibr27-0022034520962733" ref-type="bibr">Rodrigues et al. 2006</xref>;
<xref rid="bibr5-0022034520962733" ref-type="bibr">Ciszek et al. 2016</xref>;
<xref rid="bibr1-0022034520962733" ref-type="bibr">Boyer et al. 2017</xref>).
Other studies suggest that propranolol’s analgesic efficacy is modified by genetic
variation in the catechol-O-methyltransferase (<italic>COMT</italic>) gene.
Specifically, the A allele of the rs4680 single nucleotide polymorphism codes for a
valine-to-methionine substitution in the COMT enzyme, reducing enzymatic activity
and slowing catabolism of catecholamines (<xref rid="bibr20-0022034520962733" ref-type="bibr">Mannisto and Kaakkola 1999</xref>). One study
found that people with the A:A genotype had heightened sensitivity to masseter
muscle pain (<xref rid="bibr39-0022034520962733" ref-type="bibr">Zubieta et al.
2003</xref>). Likewise, a <italic>COMT</italic> haplotype coding for reduced
enzyme activity was associated with greater sensitivity to experimental pain and
increased risk of developing TMD (<xref rid="bibr9-0022034520962733" ref-type="bibr">Diatchenko et al. 2005</xref>).</p>
              <p>These studies underpinned our premise that propranolol’s analgesic efficacy is
enhanced in people whose <italic>COMT</italic> genotype is associated with reduced
enzyme activity. Initial support for the premise came from a pilot, randomized
crossover trial of 40 women with TMD who received propranolol and placebo (<xref rid="bibr35-0022034520962733" ref-type="bibr">Tchivileva et al. 2010</xref>).
Propranolol’s efficacy increased in a linear manner with each additional copy of the
<italic>COMT</italic> haplotype coding for reduced enzyme activity, consistent
with an additive genetic model (<xref rid="bibr6-0022034520962733" ref-type="bibr">Clarke et al. 2011</xref>). Additivity was likewise found in an in vitro study
in which COMT enzyme activity reduced with each additional copy of the A allele of
the <italic>COMT</italic> gene (<xref rid="bibr31-0022034520962733" ref-type="bibr">Smith et al. 2014</xref>).</p>
              <p>This study aimed to determine if <italic>COMT</italic> genotype modifies analgesic
efficacy of propranolol in a parallel-group randomized controlled trial (RCT). This
represents the second aim of the Study of Orofacial Pain and Propranolol (SOPPRANO),
in which propranolol was effective in achieving ≥30% and ≥50% reductions in TMD
patients’ facial pain (<xref rid="bibr34-0022034520962733" ref-type="bibr">Tchivileva et al. 2020</xref>). As specified a priori in the study protocol, we
hypothesized that the A allele of rs4680 is associated with greater analgesic
efficacy of propranolol.</p>
            </sec>
            <sec sec-type="methods" id="section2-0022034520962733">
              <title>Methods</title>
              <p>The study was approved by Institutional Review Boards at the 3 enrollment sites:
University of North Carolina at Chapel Hill, University of Florida, and University
at Buffalo. All study participants provided signed informed consent. Full details of
the study methods are reported elsewhere (<xref rid="bibr34-0022034520962733" ref-type="bibr">Tchivileva et al. 2020</xref>) and summarized
below using headings from the CONSORT statement (<xref rid="bibr23-0022034520962733" ref-type="bibr">Moher et al. 2010</xref>).</p>
              <p>The trial design was a double-blind, placebo-controlled, parallel-group, phase 2b
RCT. Study participants were 200 adults aged 18 to 65 y with TMD myalgia (with or
without arthralgia), as determined using the diagnostic criteria for TMD (<xref rid="bibr28-0022034520962733" ref-type="bibr">Schiffman et al. 2014</xref>).
There were 16 exclusion criteria based on propranolol’s contraindications and health
conditions that could have affected pain ratings. Study participants were randomized
using 1:1 allocation stratified by study site using fixed permutated blocks of 4.
Randomization was initiated by study coordinators via an electronic web response
system, thereby masking study personnel and all study participants. Study
participants were allocated to one of the investigational products: capsules of
60-mg extended release propranolol or a matching placebo, both administered once
daily for 1 wk and then twice daily for 8 wk.</p>
              <p>As specified a priori in the study protocol, the primary outcome was a facial pain
index, calculated as the product of daily facial pain intensity (reported on a 0 to
100 numeric rating scale) and pain duration (% of day with facial pain) divided by
100. Each was recorded in a daily pain diary, and their product (i.e., daily facial
pain index) was averaged across the 7 d prior to study visits conducted 1, 5, and 9
wk after the randomization visit. The secondary outcome was the patient’s global
impression of change (PGIC; <xref rid="bibr17-0022034520962733" ref-type="bibr">Hurst and Bolton 2004</xref>) evaluated at weeks 5 and 9.</p>
              <sec id="section3-0022034520962733">
                <title>Genotyping</title>
                <p>DNA was extracted from venous blood samples collected at the baseline visit.
Genotyping was performed by LGC Genomics (Beverly, MA, US) using proprietary
KASP™ assays based on competitive allele-specific polymerase chain reaction.</p>
              </sec>
              <sec id="section4-0022034520962733">
                <title>Statistical Methods</title>
                <p>To reduce population stratification bias (<xref rid="bibr2-0022034520962733" ref-type="bibr">Cardon and Palmer 2003</xref>), this analysis
was restricted to non-Hispanic Whites. Regression models tested for an
interaction of genotype and allocated treatment group to evaluate the hypothesis
that the A allele of rs4680 is associated with greater analgesic efficacy of
propranolol. For the primary endpoint of facial pain index, efficacy was
quantified as change in the index, computed by subtracting the baseline value
from the value at each follow-up visit (i.e., weeks 1, 5, and 9). The continuous
measure of change was analyzed as the dependent variable using a linear mixed
model for repeated measures (MMRM), while logistic MMRMs evaluated reductions of
≥30% and ≥50% relative to baseline, both of which are clinically meaningful
thresholds of improvement in pain (<xref rid="bibr11-0022034520962733" ref-type="bibr">Dworkin et al. 2009</xref>).</p>
                <p>As specified a priori in the study protocol, the number of A alleles was modeled
as a continuous fixed-effect variable (i.e., assuming an additive genetic
model). Other fixed-effect variables were treatment group (2 groups), study
visit (3 postbaseline categories), and all 2-way and 3-way interactions of
genotype, treatment group, and visit. Fixed-effect covariates were baseline pain
index (modeled as a continuous variable), study site (3 categories), and sex (2
categories). Study participants were included as a random effect. MMRMs used
data from all available follow-up visits and programming statements (<xref rid="bibr8-0022034520962733" ref-type="bibr">Davis 2014</xref>) tested for a
2-way interaction of treatment group with genotype at week 9. Other programming
statements calculated odds ratios or mean differences between treatment groups
at week 9 for each genotype. Model-adjusted mean values or proportions were
calculated and plotted for descriptive purposes. A comparable logistic MMRM was
used to analyze global impression of change, dichotomized from the 7-point
response scale to classify patients who reported feeling “somewhat better”
through “a great deal better” (<xref rid="bibr17-0022034520962733" ref-type="bibr">Hurst and Bolton 2004</xref>).</p>
                <p>To determine the efficacy across the full range of clinically meaningful
reduction in pain, logistic MMRMs for reductions ranging from ≥20% to ≥70% were
used to construct cumulative response curves (<xref rid="bibr13-0022034520962733" ref-type="bibr">Farrar 2010</xref>). The percentage area under
curve (%AUC) was calculated for each treatment group, with the %AUC difference
representing the efficacy estimate. AUC values were calculated using the
trapezoid rule, and bootstrap estimates of the standard error were obtained from
1,000 samples of the observed data. Genotype-group differences in %AUC were
evaluated using Wald’s test.</p>
                <p>The threshold for statistical significance of effect modification was
<italic>P</italic> &lt; 0.05 for the 2-tailed test of the null hypothesis of
no interaction at week 9. To judge the overall credibility of the effect
modification, we applied 11 qualitative criteria (<xref rid="bibr33-0022034520962733" ref-type="bibr">Sun et al. 2010</xref>). Sensitivity analysis
evaluated 1) our assumption of an additive genetic model, 2) components of the
facial pain index (i.e., pain intensity and duration), and 3) the effect of
restricting the sample to females, as occurred in the pilot study (<xref rid="bibr35-0022034520962733" ref-type="bibr">Tchivileva et al.
2010</xref>).</p>
              </sec>
              <sec id="section5-0022034520962733">
                <title>Sample Size Justification</title>
                <p>SOPPRANO was planned with a target sample of 200 randomized study participants,
providing 90% statistical power for the primary aim of overall analgesic
efficacy of propranolol. As initially envisaged, the sample was to be limited to
non-Hispanic Whites, providing 61% power to detect an interaction between
<italic>COMT</italic> genotype and treatment group using a threshold of
<italic>P</italic> &lt; 0.05 for type I error based on a 2-tailed test.
However, at study initiation, enrollment was opened to all races, and hence this
analysis was limited to the 143 non-Hispanic Whites, yielding power of 47% to
test the same interaction. Other assumptions for the power calculation were
based on findings from our pilot study, namely, a 1:2:1 ratio of study
participants with 0, 1, and 2 copies of the A allele of rs4680 and percentage
reductions in mean pain index of 9%, 27%, and 45% (respectively) for the
propranolol group compared with 9% for each genotype in the placebo group.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section6-0022034520962733">
              <title>Results</title>
              <sec id="section7-0022034520962733">
                <title>Baseline Characteristics of Study Groups</title>
                <p>Between August 2015 and January 2018, 200 study participants were randomized to
either propranolol (<italic>n</italic> = 100) or placebo (<italic>n</italic> =
100), and 199 study participants with follow-up data were analyzed to test
SOPPRANO’s primary aim (see the study by <xref rid="bibr34-0022034520962733" ref-type="bibr">Tchivileva et al. 2020</xref>, which includes
the CONSORT flow diagram, details of treatment adherence, and overall results
for efficacy and adverse events). This genetic analysis was limited to 143
non-Hispanic White study participants who had at least 1 follow-up visit
(<italic>n</italic> = 78 propranolol, <italic>n</italic> = 65 placebo). The
distribution of rs4680 genotypes did not depart significantly
(<italic>P</italic> &gt; 0.05) from Hardy–Weinberg equilibrium. At baseline,
the mean age of the the participants was 33 y, three-quarters were women, and
there were no meaningful differences between treatment groups in these or other
baseline characteristics (<xref rid="table1-0022034520962733" ref-type="table">Table 1</xref>). Likewise, there were only small differences in baseline
characteristics according to <italic>COMT</italic> genotype (<xref rid="table2-0022034520962733" ref-type="table">Table 2</xref>).</p>
                <table-wrap id="table1-0022034520962733" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Baseline Characteristics of Participants in the 2 Treatment Groups.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_0022034520962733-table1"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Characteristic</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 65)</th>
                          <th align="center" rowspan="1" colspan="1">Propranolol (<italic>n</italic> = 78)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="3" rowspan="1">Demographics</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Age, y</td>
                          <td rowspan="1" colspan="1">33.1 (13.0)</td>
                          <td rowspan="1" colspan="1">33.9 (12.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Sex, female</td>
                          <td rowspan="1" colspan="1">51 (78.5%)</td>
                          <td rowspan="1" colspan="1">60 (76.9%)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1"> Study site</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University of North Carolina</td>
                          <td rowspan="1" colspan="1">28 (43.1%)</td>
                          <td rowspan="1" colspan="1">39 (50.0%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University of Florida</td>
                          <td rowspan="1" colspan="1">17 (26.2%)</td>
                          <td rowspan="1" colspan="1">20 (25.6%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University at Buffalo</td>
                          <td rowspan="1" colspan="1">20 (30.8%)</td>
                          <td rowspan="1" colspan="1">19 (24.4%)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1">Facial pain symptoms</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Time since TMD onset, y</td>
                          <td rowspan="1" colspan="1">11.5 (10.6)</td>
                          <td rowspan="1" colspan="1">11.7 (10.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain index, 0-100 scale</td>
                          <td rowspan="1" colspan="1">30.0 (17.4)</td>
                          <td rowspan="1" colspan="1">31.0 (20.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain intensity, 0-100 scale</td>
                          <td rowspan="1" colspan="1">45.7 (14.8)</td>
                          <td rowspan="1" colspan="1">47.6 (14.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain duration, 0-100 scale</td>
                          <td rowspan="1" colspan="1">60.8 (24.5)</td>
                          <td rowspan="1" colspan="1">59.5 (27.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Painful days in the past 30 d, no. of days</td>
                          <td rowspan="1" colspan="1">24.1 (6.2)</td>
                          <td rowspan="1" colspan="1">24.4 (7.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Facial GCPS grade IIb-IV</td>
                          <td rowspan="1" colspan="1">39 (60.0%)</td>
                          <td rowspan="1" colspan="1">46 (59.0%)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1">DC/TMD examination findings</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Pain-free jaw opening, mm</td>
                          <td rowspan="1" colspan="1">29.3 (11.5)</td>
                          <td rowspan="1" colspan="1">29.4 (11.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Maximum unassisted jaw opening, mm</td>
                          <td rowspan="1" colspan="1">43.9 (9.6)</td>
                          <td rowspan="1" colspan="1">43.6 (9.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> TMD myalgia and arthralgia</td>
                          <td rowspan="1" colspan="1">63 (96.9%)</td>
                          <td rowspan="1" colspan="1">74 (94.9%)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1">Headache and other symptoms</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Migraine</td>
                          <td rowspan="1" colspan="1">29 (44.6%)</td>
                          <td rowspan="1" colspan="1">37 (47.4%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HIT-6, 36-78 scale</td>
                          <td rowspan="1" colspan="1">55.8 (8.5)</td>
                          <td rowspan="1" colspan="1">54.6 (9.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HADS anxiety, 0-21 scale</td>
                          <td rowspan="1" colspan="1">7.0 (4.5)</td>
                          <td rowspan="1" colspan="1">7.5 (4.1)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HADS depression, 0-21 scale</td>
                          <td rowspan="1" colspan="1">3.2 (3.2)</td>
                          <td rowspan="1" colspan="1">3.8 (3.6)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1"><italic>COMT</italic> rs4680 (Val158Met)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> G:G</td>
                          <td rowspan="1" colspan="1">12 (18.5%)</td>
                          <td rowspan="1" colspan="1">21 (26.9%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> A:G</td>
                          <td rowspan="1" colspan="1">38 (58.5%)</td>
                          <td rowspan="1" colspan="1">34 (43.6%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> A:A</td>
                          <td rowspan="1" colspan="1">15 (23.1%)</td>
                          <td rowspan="1" colspan="1">23 (29.5%)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn1-0022034520962733">
                      <p>Data are means (SDs) or <italic>n</italic> (%) of non-Hispanic White
study participants in the SOPPRANO study.</p>
                    </fn>
                    <fn id="table-fn2-0022034520962733">
                      <p><italic>COMT</italic>, catecholamine-O-methyltransferase; DC/TMD,
diagnostic criteria for TMD; GCPS, Graded Chronic Pain Scale; HADS,
Hospital Anxiety and Depression Scale; HIT-6, Headache Impact
Test–6; TMD, temporomandibular disorder.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="table2-0022034520962733" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Baseline Characteristics of Participants Classified by
<italic>COMT</italic> rs4680 Genotype.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_0022034520962733-table2"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th align="center" colspan="3" rowspan="1"><italic>COMT</italic> rs4680
Genotype</th>
                          <th rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Characteristic</th>
                          <th align="center" rowspan="1" colspan="1">G:G (<italic>n</italic> = 33)</th>
                          <th align="center" rowspan="1" colspan="1">A:G (<italic>n</italic> = 72)</th>
                          <th align="center" rowspan="1" colspan="1">A:A (<italic>n</italic> = 38)</th>
                          <th align="center" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="5" rowspan="1">Demographics</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Age, y</td>
                          <td rowspan="1" colspan="1">36.9 (12.1)</td>
                          <td rowspan="1" colspan="1">31.8 (13.1)</td>
                          <td rowspan="1" colspan="1">33.9 (11.6)</td>
                          <td rowspan="1" colspan="1">0.123</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Sex, female</td>
                          <td rowspan="1" colspan="1">26 (78.8%)</td>
                          <td rowspan="1" colspan="1">56 (77.8%)</td>
                          <td rowspan="1" colspan="1">29 (76.3%)</td>
                          <td rowspan="1" colspan="1">0.977</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Study site</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">0.163</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University of North Carolina</td>
                          <td rowspan="1" colspan="1">19 (57.6%)</td>
                          <td rowspan="1" colspan="1">29 (40.3%)</td>
                          <td rowspan="1" colspan="1">19 (50.0%)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University of Florida</td>
                          <td rowspan="1" colspan="1">7 (21.2%)</td>
                          <td rowspan="1" colspan="1">24 (33.3%)</td>
                          <td rowspan="1" colspan="1">6 (15.8%)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> University at Buffalo</td>
                          <td rowspan="1" colspan="1">7 (21.2%)</td>
                          <td rowspan="1" colspan="1">19 (26.4%)</td>
                          <td rowspan="1" colspan="1">13 (34.2%)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Allocation</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol treatment group</td>
                          <td rowspan="1" colspan="1">21 (63.6%)</td>
                          <td rowspan="1" colspan="1">34 (47.2%)</td>
                          <td rowspan="1" colspan="1">23 (60.5%)</td>
                          <td rowspan="1" colspan="1">0.104</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Facial pain symptoms</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Time since TMD onset, y</td>
                          <td rowspan="1" colspan="1">10.6 (11.5)</td>
                          <td rowspan="1" colspan="1">10.7 (9.9)</td>
                          <td rowspan="1" colspan="1">14.0 (9.9)</td>
                          <td rowspan="1" colspan="1">0.118</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain index, 0-100 scale</td>
                          <td rowspan="1" colspan="1">30.3 (19.5)</td>
                          <td rowspan="1" colspan="1">30.7 (18.5)</td>
                          <td rowspan="1" colspan="1">30.4 (19.5)</td>
                          <td rowspan="1" colspan="1">0.968</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain intensity, 0-100 scale</td>
                          <td rowspan="1" colspan="1">46.9 (15.4)</td>
                          <td rowspan="1" colspan="1">46.6 (15.0)</td>
                          <td rowspan="1" colspan="1">47.0 (14.4)</td>
                          <td rowspan="1" colspan="1">0.996</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Weekly pain duration, 0-100 scale</td>
                          <td rowspan="1" colspan="1">60.8 (28.1)</td>
                          <td rowspan="1" colspan="1">60.4 (24.5)</td>
                          <td rowspan="1" colspan="1">58.8 (27.8)</td>
                          <td rowspan="1" colspan="1">0.921</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Painful days in the last 30 d, no. of days</td>
                          <td rowspan="1" colspan="1">25.5 (6.7)</td>
                          <td rowspan="1" colspan="1">24.2 (6.0)</td>
                          <td rowspan="1" colspan="1">23.4 (7.6)</td>
                          <td rowspan="1" colspan="1">0.503</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Facial GCPS grade IIb-IV</td>
                          <td rowspan="1" colspan="1">14 (42.4%)</td>
                          <td rowspan="1" colspan="1">29 (40.3%)</td>
                          <td rowspan="1" colspan="1">15 (39.5%)</td>
                          <td rowspan="1" colspan="1">0.809</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">DC/TMD examination findings</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Pain-free jaw opening, mm</td>
                          <td rowspan="1" colspan="1">28.3 (10.1)</td>
                          <td rowspan="1" colspan="1">29.9 (11.3)</td>
                          <td rowspan="1" colspan="1">29.2 (12.7)</td>
                          <td rowspan="1" colspan="1">0.871</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Maximum unassisted jaw opening, mm</td>
                          <td rowspan="1" colspan="1">41.1 (7.6)</td>
                          <td rowspan="1" colspan="1">44.3 (10.1)</td>
                          <td rowspan="1" colspan="1">44.9 (8.6)</td>
                          <td rowspan="1" colspan="1">0.200</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> TMD myalgia and arthralgia</td>
                          <td rowspan="1" colspan="1">32 (97.0%)</td>
                          <td rowspan="1" colspan="1">70 (97.2%)</td>
                          <td rowspan="1" colspan="1">35 (92.1%)</td>
                          <td rowspan="1" colspan="1">0.685</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Headache and other symptoms</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Migraine</td>
                          <td rowspan="1" colspan="1">19 (57.6%)</td>
                          <td rowspan="1" colspan="1">37 (51.4%)</td>
                          <td rowspan="1" colspan="1">21 (55.3%)</td>
                          <td rowspan="1" colspan="1">0.715</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HIT-6, 36-78 scale</td>
                          <td rowspan="1" colspan="1">56.5 (9.7)</td>
                          <td rowspan="1" colspan="1">54.2 (8.8)</td>
                          <td rowspan="1" colspan="1">55.7 (8.5)</td>
                          <td rowspan="1" colspan="1">0.242</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HADS anxiety, 0-21 scale</td>
                          <td rowspan="1" colspan="1">8.5 (3.9)</td>
                          <td rowspan="1" colspan="1">6.7 (4.2)</td>
                          <td rowspan="1" colspan="1">7.3 (4.6)</td>
                          <td rowspan="1" colspan="1">0.194</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> HADS depression, 0-21 scale</td>
                          <td rowspan="1" colspan="1">4.3 (3.9)</td>
                          <td rowspan="1" colspan="1">3.3 (3.5)</td>
                          <td rowspan="1" colspan="1">3.1 (2.9)</td>
                          <td rowspan="1" colspan="1">0.386</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn3-0022034520962733">
                      <p>Data are means (SDs) or <italic>n</italic> (%) of non-Hispanic White
study participants in the SOPPRANO study. <italic>P</italic> values
are from 1-way analysis of variance <italic>F</italic>-tests (for
continuous variables) and chi-square tests (for categorical
variables) testing the null hypothesis that means or percentages
(respectively) are equivalent among genotypes.</p>
                    </fn>
                    <fn id="table-fn4-0022034520962733">
                      <p><italic>COMT</italic>, catecholamine-O-methyltransferase; DC/TMD,
diagnostic criteria for TMD; GCPS, Graded Chronic Pain Scale; HADS,
Hospital Anxiety and Depression Scale; HIT-6, Headache Impact
Test–6; TMD, temporomandibular disorder.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section8-0022034520962733">
                <title>Effect Modification of the Primary Endpoint by the <italic>COMT</italic>
Genotype</title>
                <p>Results for the linear MMRM analysis of the continuous measures of pain index
revealed greater efficacy for G:G homozygotes than for A:A homozygotes, although
the interaction was not statistically significant (<xref rid="table3-0022034520962733" ref-type="table">Table 3</xref>; <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/0022034520962733">Suppl. Fig. S1</ext-link>). Among the <italic>n</italic> = 33 G:G
homozygotes of rs4680, the adjusted percentage of study participants with ≥30%
reduction in facial pain index at week 9 was 30.8% in the placebo group and
83.0% in the propranolol group (<xref ref-type="fig" rid="fig1-0022034520962733">Fig. 1A</xref>), whereas among <italic>n</italic> = 38 A:A homozygotes, the
corresponding percentages were 56.1% and 51.7% (<xref ref-type="fig" rid="fig1-0022034520962733">Fig. 1C</xref>). The adjusted odds ratios of
propranolol’s efficacy were 10.9 for G:G, 3.0 for A:G, and 0.8 for A:A, and the
test for gene × treatment group interaction was statistically significant
(<italic>P</italic> = 0.035; <xref rid="table3-0022034520962733" ref-type="table">Table 3</xref>). A similar pattern was seen
using the threshold of ≥50% reduction in facial pain index to define responders:
odds ratios varied from 5.1 for G:G to 0.9 for A:A, although the test for
interaction was not significant (<italic>P</italic> = 0.354; <xref rid="table3-0022034520962733" ref-type="table">Table 3</xref>).</p>
                <table-wrap id="table3-0022034520962733" orientation="portrait" position="float">
                  <label>Table 3.</label>
                  <caption>
                    <p>Summary of Efficacy Estimates and Tests for Gene × Treatment Group
Interactions.</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_0022034520962733-table3"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th align="center" colspan="3" rowspan="1"><italic>COMT</italic> rs4680
Genotype</th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Endpoint</th>
                          <th align="center" rowspan="1" colspan="1">G:G (<italic>n</italic> = 33)</th>
                          <th align="center" rowspan="1" colspan="1">A:G (<italic>n</italic> = 72)</th>
                          <th align="center" rowspan="1" colspan="1">A:A (<italic>n</italic> = 38)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="4" rowspan="1">Mean weekly pain index, baseline to week 9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol: change from baseline, mean (95% CL)</td>
                          <td rowspan="1" colspan="1">−13.5 (–19.0, –7.9)</td>
                          <td rowspan="1" colspan="1">−11.8 (–15.3, –8.3)</td>
                          <td rowspan="1" colspan="1">−10.1 (–15.9, –4.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Placebo: change from baseline, mean (95% CL)</td>
                          <td rowspan="1" colspan="1">−4.7 (–11.9, 2.4)</td>
                          <td rowspan="1" colspan="1">−7.2 (–11.0, –3.3)</td>
                          <td rowspan="1" colspan="1">−9.6 (–16.0, –3.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol minus placebo, mean (95% CL)</td>
                          <td rowspan="1" colspan="1">−8.7 (–17.6, 0.1)</td>
                          <td rowspan="1" colspan="1">−4.6 (–9.6, 0.3)</td>
                          <td rowspan="1" colspan="1">−0.5 (–9.0, 8.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Interaction of genotype × treatment group,
<italic>P</italic> value</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">0.257</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td colspan="4" rowspan="1">≥30% reduction in weekly pain index, baseline to
week 9</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">83.0 (63.0, 93.3)</td>
                          <td rowspan="1" colspan="1">69.5 (55.8, 80.5)</td>
                          <td rowspan="1" colspan="1">51.7 (29.7, 73.0)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Placebo: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">30.8 (12.4, 58.3)</td>
                          <td rowspan="1" colspan="1">43.0 (29.4, 57.8)</td>
                          <td rowspan="1" colspan="1">56.1 (32.2, 77.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol relative to placebo, odds ratio (95% CL)</td>
                          <td rowspan="1" colspan="1">10.9 (2.4, 50.7)</td>
                          <td rowspan="1" colspan="1">3.0 (1.3, 6.8)</td>
                          <td rowspan="1" colspan="1">0.8 (0.2, 3.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Interaction of genotype × treatment group,
<italic>P</italic> value</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">0.035</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">≥50% reduction in weekly pain index, baseline to week 9</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">56.1 (35.3, 74.9)</td>
                          <td rowspan="1" colspan="1">51.4 (38.2, 64.4)</td>
                          <td rowspan="1" colspan="1">46.7 (26.2, 68.3)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Placebo: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">19.6 (6.5, 46.3)</td>
                          <td rowspan="1" colspan="1">26.0 (15.5, 40.4)</td>
                          <td rowspan="1" colspan="1">33.7 (15.3, 58.8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol relative to placebo, odds ratio (95% CL)</td>
                          <td rowspan="1" colspan="1">5.2 (1.2, 23.3)</td>
                          <td rowspan="1" colspan="1">3.0 (1.3, 6.8)</td>
                          <td rowspan="1" colspan="1">1.7 (0.4, 6.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Interaction of genotype × treatment group,
<italic>P</italic> value</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">0.354</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">≥Moderate improvement in PGIC, baseline to week 9</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">55.4 (34.6, 74.5)</td>
                          <td rowspan="1" colspan="1">44.1 (31.2, 57.8)</td>
                          <td rowspan="1" colspan="1">33.3 (16.5, 55.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Placebo: study participants responding, % (95% CL)</td>
                          <td rowspan="1" colspan="1">19.7 (6.4, 46.9)</td>
                          <td rowspan="1" colspan="1">27.0 (16.1, 41.5)</td>
                          <td rowspan="1" colspan="1">35.7 (16.5, 60.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Propranolol relative to placebo, odds ratio (95% CL)</td>
                          <td rowspan="1" colspan="1">5.1 (1.1, 22.8)</td>
                          <td rowspan="1" colspan="1">2.1 (1.0, 4.8)</td>
                          <td rowspan="1" colspan="1">0.9 (0.2, 3.6)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Interaction of genotype × treatment group,
<italic>P</italic> value</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1">0.153</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn5-0022034520962733">
                      <p>Data are estimates from linear and logistic mixed models for repeated
measures of <italic>n</italic> = 143 non-Hispanic White study
participants in the SOPPRANO study. Adjusted means, percentages, and
95% confidence limits (95% CL) were estimated from models with
predictor variables of genotype, treatment group, visit, and all
2-way and 3-way interactions. Estimate statements for each model
were used to calculate adjusted odds ratios and 95% confidence
limits at week 9. Another estimate statement tested for the 2-way
interaction of genotype and treatment group at week 9.</p>
                    </fn>
                    <fn id="table-fn6-0022034520962733">
                      <p><italic>COMT</italic>, catecholamine-O-methyltransferase; PGIC,
patient global impression of change.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig id="fig1-0022034520962733" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Change in 2 endpoints at 3 follow-up visits for study participants in 2
treatment groups stratified according to genotype of the rs4680 single
nucleotide polymorphism of <italic>COMT</italic>. Endpoints were
estimated for propranolol and placebo groups in regression
models from <italic>n</italic> = 143 non-Hispanic White study
participants in the SOPPRANO study. Endpoints were percentage of
participants with at least 30% reduction in pain index plotted for
(<bold>A</bold>) G:G homozygotes, (<bold>B</bold>) A:G
heterozygotes, and (<bold>C</bold>) A:A homozygotes and percentage of
participants reporting overall improvement, as measured by patient’s
global impression of change, in their pain condition plotted for
(<bold>D</bold>) G:G homozygotes, (<bold>E</bold>) A:G
heterozygotes, and (<bold>F</bold>) A:A homozygotes. Facial pain index
endpoints were recorded at up to 3 follow-up visits that occurred 1, 5,
and 9 wk after initiating treatment. Percentage reductions in facial
pain index were calculated relative to baseline and dichotomized to
signify the percentage of participants with ≥30% reduction. Global
impression of change was reported on a 7-point scale at weeks 5 and 9
and dichotomized to signify the percentage of participants with either
less than or at least “moderate” improvement. Adjusted percentages were
estimated from logistic mixed models for repeated measures with
predictor variables of genotype, treatment group, visit, and all 2-way
and 3-way interactions. Covariates were the study site and sex. Estimate
statements for each model were used to calculate adjusted odds ratios
and 95% confidence intervals at week 9. Another estimate statement
tested for the 2-way interaction of genotype and treatment group at week
9: for pain index, <italic>P</italic> = 0.035 for the interaction; for
global improvement, <italic>P</italic> = 0.153 for the interaction.</p>
                  </caption>
                  <graphic xlink:href="10.1177_0022034520962733-fig1"/>
                </fig>
                <p>When results were integrated for thresholds of 20% to 70% reduction in pain
index, the propranolol-versus-placebo difference in cumulative response curves
was greater for G:G homozygotes (43.7 percentage point difference in AUC, 95% CL
= 15.4, 72.1) than for A:A homozygotes (6.5 percentage point difference in AUC,
95% CL = −30.2, 43.2). This genotype difference in treatment effect estimates
was statistically significant (<italic>P</italic> = 0.003; <xref ref-type="fig" rid="fig2-0022034520962733">Fig. 2</xref>). As shown in <xref ref-type="fig" rid="fig2-0022034520962733">Figure 2</xref>, the attenuated efficacy in A:A
homozygotes compared with G:G homozygotes was due to 2 factors: a lower
probability of analgesic efficacy of propranolol and a higher probability of
placebo analgesia.</p>
                <fig id="fig2-0022034520962733" orientation="portrait" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Cumulative response curves for facial pain index among study participants
in 2 treatment groups stratified according to genotype of the rs4680
single nucleotide polymorphism of <italic>COMT</italic>:
(<bold>A</bold>) G:G homozygotes, (<bold>B</bold>) A:G heterozygotes,
and (<bold>C</bold>) A:A homozygotes. Data are from <italic>n</italic> =
143 non-Hispanic White study participants in the SOPPRANO study. The
facial pain index was recorded at 3 follow-up visits that occurred 1, 5,
and 9 wk after initiating treatment. Percentage reductions in pain index
were calculated relative to baseline and dichotomized at thresholds from
20% to 70%. For each threshold, adjusted percentages were estimated from
a logistic mixed model for repeated measures with predictor variables of
genotype, treatment group, visit, and all 2-way and 3-way interactions.
Covariates were study site and sex. Adjusted percentages were plotted,
and the area under the curve (AUC) was calculated for the propranolol
and placebo groups, with the AUC difference between treatment groups
representing the efficacy estimate. AUC values were calculated using the
trapezoid rule, and bootstrap estimates of the standard error were
obtained from 1,000 replicated samples generated by random sampling,
with replacement, of the observed data.</p>
                  </caption>
                  <graphic xlink:href="10.1177_0022034520962733-fig2"/>
                </fig>
              </sec>
              <sec id="section9-0022034520962733">
                <title>Effect Modification Analysis Using the PGIC Secondary Endpoint</title>
                <p>Model-adjusted percentages of study participants reporting at least moderate
improvement in their overall condition ranged from 19.7% (placebo) to 55.4%
(propranolol) in G:G homozygotes (<xref ref-type="fig" rid="fig1-0022034520962733">Fig. 1D</xref>), with a corresponding odds ratio
of 5.1 (95% CL = 1.1, 22.8; <xref rid="table3-0022034520962733" ref-type="table">Table 3</xref>). Odds ratios were 2.1 (95% CL = 1.0, 4.8) for A:G
heterozygotes (<xref ref-type="fig" rid="fig1-0022034520962733">Fig 1E</xref>:)
and 0.9 (95% CL = 0.2, 3.6) for A:A homozygotes (<xref ref-type="fig" rid="fig1-0022034520962733">Fig. 1F</xref>), although the interaction of
genotype and treatment group at week 9 was not statistically significant
(<italic>P</italic> = 0.153, <xref rid="table3-0022034520962733" ref-type="table">Table 3</xref>).</p>
              </sec>
              <sec id="section10-0022034520962733">
                <title>Qualitative Evaluation of Credibility of the Overall Findings</title>
                <p>The analysis fulfilled all 5 study design criteria used to evaluate the
credibility of effect modification in RCTs (<xref rid="bibr33-0022034520962733" ref-type="bibr">Sun et al. 2010</xref>), namely, 1)
<italic>COMT</italic> genotype, the effect modifier, was measured at
baseline; 2) efficacy was compared among subgroups within this study; 3) the
hypothesis and 4) direction of the effect modification were specified a priori;
and 5) the <italic>COMT</italic> genotype was the single effect modifier tested.
There was mixed support for 2 analytic criteria (<xref rid="bibr33-0022034520962733" ref-type="bibr">Sun et al. 2010</xref>), namely, 6)
<italic>P</italic> values were significant at the <italic>P</italic> &lt;
0.05 threshold for only 2 of the 5 analyses; 7) however, because those 2
analyses used the facial pain index, results were strongly correlated. There was
also support for the contextual criteria (<xref rid="bibr33-0022034520962733" ref-type="bibr">Sun et al. 2010</xref>), namely, 8) subgroup
differences in effect estimates were large (e.g., odds ratios differed at least
5-fold across genotypes), 9) the interaction was consistent for the analysis of
the secondary endpoint, and 10) there was a biological rationale for the
hypothesized interaction. Overall, there is only moderate credibility of the
effect modification because it was opposite to the hypothesized direction.</p>
              </sec>
              <sec id="section11-0022034520962733">
                <title>Sensitivity Analysis</title>
                <p>When the <italic>COMT</italic> genotype was modeled as 3 categories, hence making
no assumptions about the genetic model, estimates were very similar to the
additive model (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/0022034520962733">Suppl. Table. S1</ext-link>). Specifically, efficacy at week 9 was greatest
for the G:G genotype, intermediate for the A:G genotype, and least for the A:A
genotype. Results for the components of the facial pain index were similar to
the index itself (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/0022034520962733">Suppl. Table S2</ext-link>), and findings did not change appreciably when
data were restricted to females (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/0022034520962733">Suppl. Table S3</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section12-0022034520962733">
              <title>Discussion</title>
              <p>This RCT of study participants with painful TMD found some evidence that
propranolol’s analgesic efficacy was modified by <italic>COMT</italic> genotype.
Specifically, the A allele of rs4680 was associated with reduced efficacy, with the
consequence that propranolol was superior to placebo in reducing the facial pain
index among G:G homozygotes but not among A:A homozygotes. Although this constituted
clinically meaningful differences in the magnitude of propranolol’s efficacy, the
observed antagonistic effect of the A allele is counter to the hypothesized
direction of effect modification.</p>
              <p>Before considering the implications of this unexpected finding, the study’s
limitations warrant consideration. For this secondary genetic objective, the
statistical analysis plan specified that the primary endpoint be analyzed both as a
continuous measure and after dichotomizing it at thresholds of ≥30% and ≥50% pain
reduction. The 3 endpoints were consistent in showing antagonistic directions of
effect for the A allele, although the gene × treatment group interaction was
statistically significant only for the ≥30% threshold and in secondary analysis of
cumulative response curves. This is counter to the conventional expectation that
continuous variables yield greater statistical power (<xref rid="bibr32-0022034520962733" ref-type="bibr">Snapinn and Jiang 2007</xref>). However, as noted
for the primary paper from this study (<xref rid="bibr34-0022034520962733" ref-type="bibr">Tchivileva et al. 2020</xref>), many study
participants in the placebo group experienced reductions of &lt;30% in the facial
pain index, thereby reducing the efficacy signal from the continuous endpoint.
Instead, there was greater power to detect a ≥30% reduction in pain, a measure that
is favored as clinically meaningful for patients (<xref rid="bibr11-0022034520962733" ref-type="bibr">Dworkin et al. 2009</xref>). In addition,
calculated statistical power for effect modification was only 47% using the
continuous endpoint. Nonetheless, the binary endpoint revealed statistically
significant gene × treatment group interactions that were consistent with clinically
meaningful differences in efficacy, although 95% confidence intervals were wide,
making the estimates imprecise. However, we caution against overinterpreting the
interaction <italic>P</italic> values that are less than 0.05 Instead, when all
relevant criteria were considered (<xref rid="bibr33-0022034520962733" ref-type="bibr">Sun et al. 2010</xref>), we found only moderately
credible evidence for effect modification.</p>
              <p>The current study has several strengths, including its randomized, placebo-controlled
design with allocation concealment and masking. Consistent with the best practices
for clinical trials of pain (<xref rid="bibr12-0022034520962733" ref-type="bibr">Edwards et al. 2016</xref>), the primary endpoint was measured using daily pain
diaries. The 9-wk follow-up period exceeded the minimum of 4 wk recommended for
phase 2b trials (<xref rid="bibr14-0022034520962733" ref-type="bibr">Gewandter et
al. 2014</xref>). Pain-related characteristics measured at baseline did not
differ appreciably between the treatment groups or COMT genotypes, making it
unlikely that the gene × treatment group interaction was confounded by those
characteristics. The sensitivity analysis revealed very similar results for
different genetic models, and we therefore favor the additive model because it
parsimoniously depicts the biological gradient.</p>
              <p>The opposing directions of effect modification in the current and pilot study require
scrutiny. Although both studies used the same endpoint, there were notable
differences: the pilot study used a crossover design, enrollment was restricted to
40 women, the dose of propranolol was lower, and efficacy was analyzed after 1 wk.
In general, parallel-group designs are favored for clinical trials because they
require fewer assumptions when testing efficacy (<xref rid="bibr10-0022034520962733" ref-type="bibr">Dubey 1986</xref>). The pilot study (<xref rid="bibr35-0022034520962733" ref-type="bibr">Tchivileva et al. 2010</xref>)
used a haplotype of <italic>COMT</italic> as the genetic marker, although the result
for rs4680 was similar and hence does not account for the discrepancy with this
study. In the current study, neither sex nor efficacy signals after 1 wk could
account for the discrepancy.</p>
              <p>A more salient difference between studies was the placebo group’s response: in the
pilot study, there was effectively no reduction in facial pain in the placebo phase,
whereas in the current study, there were substantial reductions in facial pain in
the placebo group. In this study, the absence of efficacy for the A:A homozygotes
was due as much to a heightened response (relative to G:G homozygotes) in the
placebo group as it was to a diminished response in the propranolol group. Sizable
responses in placebo groups are the norm in clinical trials of pain, suggesting that
the antagonistic effect of the A allele seen here is more credible than the
amplifying effect suggested by the pilot study. This effect of <italic>COMT</italic>
on treatment response in the placebo group has parallels with a clinical trial of
acupuncture for treatment of irritable bowel syndrome (<xref rid="bibr15-0022034520962733" ref-type="bibr">Hall et al. 2012</xref>) and a study of
experimentally induced placebo hypoalgesia in healthy human volunteers (<xref rid="bibr7-0022034520962733" ref-type="bibr">Colloca et al. 2019</xref>).</p>
              <p>Seemingly inconsistent effects of <italic>COMT</italic> have been reported in other
clinical settings. One review concluded that the A allele of rs4680 is associated
with a lower requirement for opioids in patients with a range of acute and chronic
pain conditions (<xref rid="bibr37-0022034520962733" ref-type="bibr">Vieira et al.
2019</xref>), whereas a subsequent study reported an opposing effect of the
allele in postsurgical pain management (<xref rid="bibr21-0022034520962733" ref-type="bibr">Matic et al. 2020</xref>). Likewise, systematic
reviews of treatment for chronic postsurgical pain (<xref rid="bibr4-0022034520962733" ref-type="bibr">Chidambaran et al. 2019</xref>) and neuropathic
pain (<xref rid="bibr36-0022034520962733" ref-type="bibr">Veluchamy et al.
2018</xref>) have reported opposing directions of association with the rs4680
genotype. Authors have speculated that the differences might be due to insufficient
power (<xref rid="bibr19-0022034520962733" ref-type="bibr">Landau et al.
2013</xref>), heterogeneity of patient populations (<xref rid="bibr4-0022034520962733" ref-type="bibr">Chidambaran et al. 2019</xref>), or interactions
with other pain regulatory systems (<xref rid="bibr21-0022034520962733" ref-type="bibr">Matic et al. 2020</xref>).</p>
              <p>Compared with the pilot study, these results provide stronger evidence that
<italic>COMT</italic> modifies the analgesic efficacy of propranolol. It might
therefore seem logical to recommend propranolol to TMD patients with A:G or G:G
genotypes of rs4680. However, we caution that any such interpretation is premature.
Instead, the contradictory directions of <italic>COMT</italic>’s effects seen here
and in other pain studies demonstrate the need for biological and clinical research
to reconcile the differences. This conclusion echoes a more general caution that
“any plan to incorporate genotyping information into clinical pain practice is
premature” (<xref rid="bibr22-0022034520962733" ref-type="bibr">Mogil 2009</xref>).
Indeed, this study adds to the enigma of <italic>COMT</italic> by revealing an
antagonistic effect of the A allele of rs4680 on propranolol’s efficacy. The finding
highlights the need for better knowledge of <italic>COMT’s</italic> role in pain
pathogenesis if the gene is to be used for a precision medicine approach to TMD.</p>
            </sec>
            <sec id="section13-0022034520962733">
              <title>Author Contributions</title>
              <p>G.D. Slade, contributed to conception, design, data analysis, and interpretation,
drafted and critically revised the manuscript; R.B. Fillingim, R. Ohrbach,
contributed to conception, design, data acquisition, and interpretation, critically
revised the manuscript; H. Hadgraft, contributed to data acquisition, critically
revised the manuscript; J. Willis, contributed to data analysis, critically revised
the manuscript; S.J. Arbes Jr., contributed to conception, design, and data
interpretation, critically revised the manuscript; I.E. Tchivileva, contributed to
conception, design, data acquisition, and interpretation, drafted and critically
revised the manuscript. All authors gave final approval and agree to be accountable
for all aspects of the work.</p>
            </sec>
            <sec sec-type="supplementary-material" id="section14-0022034520962733" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material content-type="local-data" id="suppl1-0022034520962733">
                <caption>
                  <title>DS_10.1177_0022034520962733 – Supplemental material for COMT Genotype and
Efficacy of Propranolol for TMD Pain: A Randomized Trial</title>
                </caption>
                <media xlink:href="DS_10.1177_0022034520962733.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, DS_10.1177_0022034520962733 for COMT Genotype and Efficacy
of Propranolol for TMD Pain: A Randomized Trial by G.D. Slade, R.B. Fillingim,
R. Ohrbach, H. Hadgraft, J. Willis, S.J. Arbes and I.E. Tchivileva in Journal of
Dental Research</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors thank the SOPPRANO research staff and patients who participated in the
trial. The authors also thank cardiologists Drs. Alan Hinderliter (UNC at Chapel
Hill), David Sheps (University of Florida), and Thomas Cimato (University at
Buffalo) for monitoring participants’ safety.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p>A supplemental appendix to this article is available online.</p>
              </fn>
              <fn fn-type="other">
                <p>The trial is registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>,
NCT02437383. Full details of the trial protocol are available at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of Conflicting Interests:</bold><?release-delay 12|0?>The authors declared no potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: Funding for this study
was provided by the National Institutes of Health (NIH)/National Institute of
Dental and Craniofacial Research (NIDCR) R34-DE022088 and U01-DE 024169
grants.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> S.J. Arbes Jr. <inline-graphic xlink:href="10.1177_0022034520962733-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-7767-0959">https://orcid.org/0000-0001-7767-0959</ext-link></p>
                <p>I.E. Tchivileva <inline-graphic xlink:href="10.1177_0022034520962733-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-0968-0594">https://orcid.org/0000-0003-0968-0594</ext-link></p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>N</given-names></name><name><surname>Signoret-Genest</surname><given-names>J</given-names></name><name><surname>Artola</surname><given-names>A</given-names></name><name><surname>Dallel</surname><given-names>R</given-names></name><name><surname>Monconduit</surname><given-names>L</given-names></name></person-group>. <year>2017</year>. <article-title>Propranolol treatment
prevents chronic central sensitization induced by repeated dural
stimulation</article-title>. <source>Pain</source>.
<volume>158</volume>(<issue>10</issue>):<fpage>2025</fpage>–<lpage>2034</lpage>.<pub-id pub-id-type="pmid">28700539</pub-id></mixed-citation>
              </ref>
              <ref id="bibr2-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Palmer</surname><given-names>LJ</given-names></name></person-group>. <year>2003</year>. <article-title>Population stratification and
spurious allelic association</article-title>. <source>Lancet</source>.
<volume>361</volume>(<issue>9357</issue>):<fpage>598</fpage>–<lpage>604</lpage>.<pub-id pub-id-type="pmid">12598158</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-0022034520962733">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chaplan</surname><given-names>SR</given-names></name><name><surname>Eckert</surname><given-names>WA</given-names></name><name><surname>Carruthers</surname><given-names>NI</given-names></name></person-group>. <year>2010</year>. <article-title>Drug discovery and
development for pain</article-title>. In: <person-group person-group-type="editor"><name><surname>Kruger</surname><given-names>L</given-names></name><name><surname>Light</surname><given-names>AR</given-names></name></person-group>, editors. <source>Translational pain research: from mouse to
man</source>. <publisher-loc>Boca Raton (FL)</publisher-loc>:
<publisher-name>CRC Press</publisher-name>.</mixed-citation>
              </ref>
              <ref id="bibr4-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chidambaran</surname><given-names>V</given-names></name><name><surname>Gang</surname><given-names>Y</given-names></name><name><surname>Pilipenko</surname><given-names>V</given-names></name><name><surname>Ashton</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group>. <year>2019</year>. <article-title>Systematic review and
meta-analysis of genetic risk of developing chronic postsurgical
pain</article-title>. <source>J Pain</source>.
<volume>21</volume>(1–2):<fpage>2</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">31129315</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciszek</surname><given-names>BP</given-names></name><name><surname>O’Buckley</surname><given-names>SC</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name></person-group>. <year>2016</year>. <article-title>Persistent
catechol-O-methyltransferase-dependent pain is initiated by peripheral
beta-adrenergic receptors</article-title>. <source>Anesthesiology</source>.
<volume>124</volume>(<issue>5</issue>):<fpage>1122</fpage>–<lpage>1135</lpage>.<pub-id pub-id-type="pmid">26950706</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>GM</given-names></name><name><surname>Anderson</surname><given-names>CA</given-names></name><name><surname>Pettersson</surname><given-names>FH</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Zondervan</surname><given-names>KT</given-names></name></person-group>. <year>2011</year>. <article-title>Basic statistical analysis in
genetic case-control studies</article-title>. <source>Nat Protoc</source>.
<volume>6</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="pmid">21293453</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colloca</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Martinez</surname><given-names>PE</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Ryan</surname><given-names>KA</given-names></name><name><surname>Hodgkinson</surname><given-names>C</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Dorsey</surname><given-names>SG</given-names></name></person-group>. <year>2019</year>. <article-title>OPRM1 rs1799971, COMT rs4680,
and FAAH rs324420 genes interact with placebo procedures to induce
hypoalgesia</article-title>. <source>Pain</source>.
<volume>160</volume>(<issue>8</issue>):<fpage>1824</fpage>–<lpage>1834</lpage>.<pub-id pub-id-type="pmid">31335650</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-0022034520962733">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>S</given-names></name></person-group>. <year>2014</year>. <article-title>Mixed models for repeated
measures using categorical time effects (MMRM)</article-title>. In:
<person-group person-group-type="editor"><name><surname>O’Kelly</surname><given-names>M</given-names></name><name><surname>Ratitch</surname><given-names>B</given-names></name></person-group>, editors. <source>Clinical trials with missing data: a guide for
practitioners</source>. <publisher-loc>Chichester (UK)</publisher-loc>:
<publisher-name>John Wiley &amp; Sons</publisher-name>. p.
<fpage>131</fpage>–<lpage>184</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr9-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Slade</surname><given-names>GD</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name><name><surname>Bhalang</surname><given-names>K</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Belfer</surname><given-names>I</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Shabalina</surname><given-names>SA</given-names></name><name><surname>Shagin</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>. <year>2005</year>. <article-title>Genetic
basis for individual variations in pain perception and the development of a
chronic pain condition</article-title>. <source>Hum Mol Genet</source>.
<volume>14</volume>(<issue>1</issue>):<fpage>135</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">15537663</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubey</surname><given-names>S</given-names></name></person-group>. <year>1986</year>. <article-title>Current thoughts on crossover
designs</article-title>. <source>Clin Res Regul Aff</source>.
<volume>4</volume>(<issue>2</issue>):<fpage>127</fpage>–<lpage>142</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr11-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>MP</given-names></name><name><surname>Peirce-Sandner</surname><given-names>S</given-names></name><name><surname>Burke</surname><given-names>LB</given-names></name><name><surname>Cowan</surname><given-names>P</given-names></name><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Hertz</surname><given-names>S</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Rappaport</surname><given-names>BA</given-names></name></person-group>, <etal>et al</etal>. <year>2009</year>.
<article-title>Interpreting the clinical importance of group differences in
chronic pain clinical trials: IMMPACT recommendations</article-title>.
<source>Pain</source>.
<volume>146</volume>(<issue>3</issue>):<fpage>238</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">19836888</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RR</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>Angst</surname><given-names>MS</given-names></name><name><surname>Dionne</surname><given-names>R</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Hansson</surname><given-names>P</given-names></name><name><surname>Haroutounian</surname><given-names>S</given-names></name><name><surname>Arendt-Nielsen</surname><given-names>L</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <year>2016</year>. <article-title>Patient
phenotyping in clinical trials of chronic pain treatments: IMMPACT
recommendations</article-title>. <source>Pain</source>.
<volume>157</volume>(<issue>9</issue>):<fpage>1851</fpage>–<lpage>1871</lpage>.<pub-id pub-id-type="pmid">27152687</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>JT</given-names></name></person-group>. <year>2010</year>. <article-title>Advances in clinical research
methodology for pain clinical trials</article-title>. <source>Nat
Med</source>.
<volume>16</volume>(<issue>11</issue>):<fpage>1284</fpage>–<lpage>1293</lpage>.<pub-id pub-id-type="pmid">20948532</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gewandter</surname><given-names>JS</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>MP</given-names></name><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Gastonguay</surname><given-names>MR</given-names></name><name><surname>Gilron</surname><given-names>I</given-names></name><name><surname>Katz</surname><given-names>NP</given-names></name><name><surname>Mehta</surname><given-names>C</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name></person-group>, <etal>et al</etal>. <year>2014</year>. <article-title>Research
designs for proof-of-concept chronic pain clinical trials: IMMPACT
recommendations</article-title>. <source>Pain</source>.
<volume>155</volume>(<issue>9</issue>):<fpage>1683</fpage>–<lpage>1695</lpage>.<pub-id pub-id-type="pmid">24865794</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>KT</given-names></name><name><surname>Lembo</surname><given-names>AJ</given-names></name><name><surname>Kirsch</surname><given-names>I</given-names></name><name><surname>Ziogas</surname><given-names>DC</given-names></name><name><surname>Douaiher</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>KB</given-names></name><name><surname>Conboy</surname><given-names>LA</given-names></name><name><surname>Kelley</surname><given-names>JM</given-names></name><name><surname>Kokkotou</surname><given-names>E</given-names></name><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name></person-group>. <year>2012</year>. <article-title>Catechol-O-methyltransferase
val158met polymorphism predicts placebo effect in irritable bowel
syndrome</article-title>. <source>PLoS One</source>.
<volume>7</volume>(<issue>10</issue>):<fpage>e48135</fpage>.<pub-id pub-id-type="pmid">23110189</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group>. <year>2017</year>. <article-title>Unveiling the relative
efficacy, safety and tolerability of prophylactic medications for migraine:
pairwise and network-meta analysis</article-title>. <source>J Headache
Pain</source>.
<volume>18</volume>(<issue>1</issue>):<fpage>26</fpage>.<pub-id pub-id-type="pmid">28220376</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>H</given-names></name><name><surname>Bolton</surname><given-names>J</given-names></name></person-group>. <year>2004</year>. <article-title>Assessing the clinical
significance of change scores recorded on subjective outcome
measures</article-title>. <source>J Manipulative Physiol Ther</source>.
<volume>27</volume>(<issue>1</issue>):<fpage>26</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">14739871</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khasar</surname><given-names>SG</given-names></name><name><surname>McCarter</surname><given-names>G</given-names></name><name><surname>Levine</surname><given-names>JD</given-names></name></person-group>. <year>1999</year>. <article-title>Epinephrine produces a
beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro
sensitization of rat nociceptors</article-title>. <source>J
Neurophysiol</source>.
<volume>81</volume>(<issue>3</issue>):<fpage>1104</fpage>–<lpage>1112</lpage>.<pub-id pub-id-type="pmid">10085337</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>SK</given-names></name><name><surname>Blouin</surname><given-names>JL</given-names></name><name><surname>Carvalho</surname><given-names>B</given-names></name></person-group>. <year>2013</year>. <article-title>The effect of OPRM1 and COMT
genotypes on the analgesic response to intravenous fentanyl labor
analgesia</article-title>. <source>Anesth Analg</source>.
<volume>116</volume>(<issue>2</issue>):<fpage>386</fpage>–<lpage>391</lpage>.<pub-id pub-id-type="pmid">23302985</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannisto</surname><given-names>PT</given-names></name><name><surname>Kaakkola</surname><given-names>S</given-names></name></person-group>. <year>1999</year>. <article-title>Catechol-O-methyltransferase
(COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy
of the new selective COMT inhibitors</article-title>. <source>Pharmacol
Rev</source>.
<volume>51</volume>(<issue>4</issue>):<fpage>593</fpage>–<lpage>628</lpage>.<pub-id pub-id-type="pmid">10581325</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matic</surname><given-names>M</given-names></name><name><surname>de Hoogd</surname><given-names>S</given-names></name><name><surname>de Wildt</surname><given-names>SN</given-names></name><name><surname>Tibboel</surname><given-names>D</given-names></name><name><surname>Knibbe</surname><given-names>CA</given-names></name><name><surname>van Schaik</surname><given-names>RH</given-names></name></person-group>. <year>2020</year>. <article-title>OPRM1 and COMT polymorphisms:
implications on postoperative acute, chronic and experimental pain after
cardiac surgery</article-title>. <source>Pharmacogenomics</source>.
<volume>21</volume>(<issue>3</issue>):<fpage>181</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">31967515</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogil</surname><given-names>JS</given-names></name></person-group>. <year>2009</year>. <article-title>Are we getting anywhere in
human pain genetics?</article-title><source>Pain</source>.
<volume>146</volume>(<issue>3</issue>):<fpage>231</fpage>–<lpage>232</lpage>.<pub-id pub-id-type="pmid">19679395</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Hopewell</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Montori</surname><given-names>V</given-names></name><name><surname>Gøtzsche</surname><given-names>PC</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Elbourne</surname><given-names>D</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group>. <year>2010</year>. <article-title>CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials</article-title>. <source>BMJ</source>.
<volume>340</volume>:<fpage>c869</fpage>.<pub-id pub-id-type="pmid">20332511</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mujakperuo</surname><given-names>HR</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>R</given-names></name><name><surname>Macfarlane</surname><given-names>TV</given-names></name></person-group>. <year>2010</year>. <article-title>Pharmacological interventions
for pain in patients with temporomandibular disorders</article-title>.
<source>Cochrane Database Syst Rev</source>.
(<issue>10</issue>):CD004715.</mixed-citation>
              </ref>
              <ref id="bibr25-0022034520962733">
                <mixed-citation publication-type="book"><collab>National Academies of Sciences, Engineering and Medicine</collab>.
<year>2020</year>. <article-title>Temporomandibular disorders: priorities
for research and care</article-title>. <publisher-loc>Washington
(DC)</publisher-loc>: <publisher-name>National Academies
Press</publisher-name>.</mixed-citation>
              </ref>
              <ref id="bibr26-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niculescu</surname><given-names>AB</given-names></name><name><surname>Le-Niculescu</surname><given-names>H</given-names></name><name><surname>Levey</surname><given-names>DF</given-names></name><name><surname>Roseberry</surname><given-names>K</given-names></name><name><surname>Soe</surname><given-names>KC</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>F</given-names></name><name><surname>Jones</surname><given-names>T</given-names></name><name><surname>Judd</surname><given-names>S</given-names></name><name><surname>McCormick</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>. <year>2019</year>. <article-title>Towards
precision medicine for pain: diagnostic biomarkers and repurposed
drugs</article-title>. <source>Mol Psychiatry</source>.
<volume>24</volume>(<issue>4</issue>):<fpage>501</fpage>–<lpage>522</lpage>.<pub-id pub-id-type="pmid">30755720</pub-id></mixed-citation>
              </ref>
              <ref id="bibr27-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>LL</given-names></name><name><surname>Oliveira</surname><given-names>MC</given-names></name><name><surname>Pelegrini-da-Silva</surname><given-names>A</given-names></name><name><surname>de Arruda Veiga</surname><given-names>MC</given-names></name><name><surname>Parada</surname><given-names>CA</given-names></name><name><surname>Tambeli</surname><given-names>CH</given-names></name></person-group>. <year>2006</year>. <article-title>Peripheral sympathetic
component of the temporomandibular joint inflammatory pain in
rats</article-title>. <source>J Pain</source>.
<volume>7</volume>(<issue>12</issue>):<fpage>929</fpage>–<lpage>936</lpage>.<pub-id pub-id-type="pmid">17157779</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>E</given-names></name><name><surname>Ohrbach</surname><given-names>R</given-names></name><name><surname>Truelove</surname><given-names>E</given-names></name><name><surname>Look</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Goulet</surname><given-names>JP</given-names></name><name><surname>List</surname><given-names>T</given-names></name><name><surname>Svensson</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>Y</given-names></name><name><surname>Lobbezoo</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>. <year>2014</year>.
<article-title>Diagnostic criteria for temporomandibular disorders (DC/TMD)
for clinical and research applications: recommendations of the international
RDC/TMD consortium network* and orofacial pain special interest
groupdagger</article-title>. <source>J Oral Facial Pain Headache</source>.
<volume>28</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">24482784</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>KG</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <year>2005</year>. <article-title>Propranolol modulates
trigeminovascular responses in thalamic ventroposteromedial nucleus: a role
in migraine?</article-title><source>Brain</source>. <volume>128</volume>(Pt
1):<fpage>86</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">15574468</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-0022034520962733">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Slade</surname><given-names>G</given-names></name><name><surname>Durham</surname><given-names>J</given-names></name></person-group>. <year>2020</year>. <article-title>Prevalence, impact, and costs
of treatment for temporomandibular disorders</article-title>. In:
<source>Temporomandibular disorders: priorities for research and
care</source>. <publisher-loc>Washington (DC)</publisher-loc>:
<publisher-name>National Academies Press</publisher-name>.</mixed-citation>
              </ref>
              <ref id="bibr31-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Reenila</surname><given-names>I</given-names></name><name><surname>Mannisto</surname><given-names>PT</given-names></name><name><surname>Slade</surname><given-names>GD</given-names></name><name><surname>Maixner</surname><given-names>W</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Nackley</surname><given-names>AG</given-names></name></person-group>. <year>2014</year>. <article-title>Epistasis between
polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and
pain</article-title>. <source>Pain</source>.
<volume>155</volume>(<issue>11</issue>):<fpage>2390</fpage>–<lpage>2399</lpage>.<pub-id pub-id-type="pmid">25218601</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snapinn</surname><given-names>SM</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name></person-group>. <year>2007</year>. <article-title>Responder analyses and the
assessment of a clinically relevant treatment effect</article-title>.
<source>Trials</source>.
<volume>8</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">17961249</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name></person-group>. <year>2010</year>. <article-title>Is a subgroup effect
believable? Updating criteria to evaluate the credibility of subgroup
analyses</article-title>. <source>BMJ</source>. 340:c117.</mixed-citation>
              </ref>
              <ref id="bibr34-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchivileva</surname><given-names>IE</given-names></name><name><surname>Hadgraft</surname><given-names>H</given-names></name><name><surname>Lim</surname><given-names>PF</given-names></name><name><surname>Di Giosia</surname><given-names>M</given-names></name><name><surname>Ribeiro-Dasilva</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>JH</given-names></name><name><surname>Willis</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>R</given-names></name><name><surname>Herman-Giddens</surname><given-names>M</given-names></name><name><surname>Fillingim</surname><given-names>RB</given-names></name></person-group>, <etal>et al</etal>. <year>2020</year>. <article-title>Efficacy
and safety of propranolol for treatment of temporomandibular disorder pain:
a randomized, placebo-controlled clinical trial</article-title>.
<source>Pain</source>.
<volume>161</volume>(<issue>8</issue>):<fpage>1755</fpage>–<lpage>1767</lpage>.<pub-id pub-id-type="pmid">32701836</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchivileva</surname><given-names>IE</given-names></name><name><surname>Lim</surname><given-names>PF</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Slade</surname><given-names>GD</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>McLean</surname><given-names>SA</given-names></name><name><surname>Maixner</surname><given-names>W</given-names></name></person-group>. <year>2010</year>. <article-title>Effect of
catechol-O-methyltransferase polymorphism on response to propranolol therapy
in chronic musculoskeletal pain: a randomized, double-blind,
placebo-controlled, crossover pilot study</article-title>.
<source>Pharmacogenet Genom</source>.
<volume>20</volume>(<issue>4</issue>):<fpage>239</fpage>–<lpage>248</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr36-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veluchamy</surname><given-names>A</given-names></name><name><surname>Hebert</surname><given-names>HL</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Palmer</surname><given-names>CNA</given-names></name><name><surname>Smith</surname><given-names>BH</given-names></name></person-group>. <year>2018</year>. <article-title>Systematic review and
meta-analysis of genetic risk factors for neuropathic pain</article-title>.
<source>Pain</source>.
<volume>159</volume>(<issue>5</issue>):<fpage>825</fpage>–<lpage>848</lpage>.<pub-id pub-id-type="pmid">29351172</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>CMP</given-names></name><name><surname>Fragoso</surname><given-names>RM</given-names></name><name><surname>Pereira</surname><given-names>D</given-names></name><name><surname>Medeiros</surname><given-names>R</given-names></name></person-group>. <year>2019</year>. <article-title>Pain polymorphisms and
opioids: an evidence based review</article-title>. <source>Mol Med
Rep</source>.
<volume>19</volume>(<issue>3</issue>):<fpage>1423</fpage>–<lpage>1434</lpage>.<pub-id pub-id-type="pmid">30592275</pub-id></mixed-citation>
              </ref>
              <ref id="bibr38-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilentz</surname><given-names>JB</given-names></name><name><surname>Cowley</surname><given-names>AW</given-names><suffix>Jr.</suffix></name></person-group><year>2017</year>. <article-title>How can precision medicine be applied to
temporomandibular disorders and its comorbidities?</article-title><source>Mol Pain</source>.
<volume>13</volume>:<fpage>1744806917710094</fpage>.<pub-id pub-id-type="pmid">28741410</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-0022034520962733">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zubieta</surname><given-names>JK</given-names></name><name><surname>Heitzeg</surname><given-names>MM</given-names></name><name><surname>Smith</surname><given-names>YR</given-names></name><name><surname>Bueller</surname><given-names>JA</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Stohler</surname><given-names>CS</given-names></name><name><surname>Goldman</surname><given-names>D</given-names></name></person-group>. <year>2003</year>. <article-title>COMT val158met genotype
affects mu-opioid neurotransmitter responses to a pain
stressor</article-title>. <source>Science</source>.
<volume>299</volume>(<issue>5610</issue>):
<fpage>1240</fpage>–<lpage>1243</lpage>.<pub-id pub-id-type="pmid">12595695</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
